Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
91-105 of 249
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiersAdvancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
On the Frontlines of Multiple SclerosisAdvancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Tirisham V. Gyang, MD
Gates B. Colbert, MD
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
On the Frontlines of Multiple SclerosisPrevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Vikram V. Bhise, MD
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
On the Frontlines of Multiple SclerosisEvolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
Ashley Baker, MSN, PMHNP
Jay Avasarala, MD, PhD
Genetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
Clinician's RoundtableGenetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
Jennifer M. Kalish, MD, PhD, FAAP
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
NeuroFrontiersGenetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
Sergio Baranzini, PhD
- advertisement
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiersUnderstanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Michael Levy, MD, PhD
Modern MS Management: Leveraging Technology to Support Brain Health
On the Frontlines of Multiple SclerosisModern MS Management: Leveraging Technology to Support Brain Health
Victoria Leavitt, PhD
Gates B. Colbert, MD
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiersTiming Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiersDecoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Ryan Quigley
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiersClemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiersAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Marc Haut, PhD
- advertisement
Addressing Barriers to MenB and MenACWY Vaccination
VacciNationAddressing Barriers to MenB and MenACWY Vaccination
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
NeuroFrontiersTransforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
Marc Haut, PhD
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiersThe Future of MS Management: Novel Agents and Clinical Approaches
Marisa McGinley, DO
